Medifast (MED) Reports In-Line Q2 EPS; Issues Mixed Outlook

Medifast (NYSE: MED) reported Q2 EPS of $0.48, in-line with the analyst estimate of $0.48. Revenue for the quarter came in at $72.2 million versus the consensus estimate of $72.79 million.

Medifast sees Q3 2015 EPS of $0.40-$0.43, versus the consensus of $0.47. Medifast sees Q3 2015 revenue of $65-68 million, versus the consensus of $71.5 million.

Medifast sees FY2015 EPS of $1.70-$1.80, versus the consensus of $1.80. Medifast sees FY2015 revenue of $270-280 million, versus the consensus of $285.55 million.

"We are pleased with our solid results in the second quarter which were in-line with our revenue and earnings expectations," said Michael C. MacDonald, Medifast Chairman and Chief Executive Officer. "We continued to make progress on our strategic initiatives within each of our key areas of focus, while also maintaining a strong financial discipline across our business. We believe that these efforts will help grow and improve Take Shape for Life, optimize Medifast Direct, and further our product and program innovation to position Medifast for success in 2015 and beyond."

For earnings history and earnings-related data on Medifast (MED) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c